Biocon (BIOCON) investor relations material

Executive summary

• Q4 FY 2026 marked a strong close with resilient operating performance amid volatile macro conditions and successful integration of biosimilars and generics businesses within 100 days.

• Transitioned to a unified biopharma entity with a stronger balance sheet, improved leverage, and integrated global commercial footprint.

• Major investment and capacity build-out phase is substantially complete, shifting focus to execution, utilization, and margin expansion.

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 were approved, with unqualified audit opinions from statutory auditors.

• Board recommended a final dividend of Rs. 0.50 per equity share for FY26, subject to shareholder approval.

Financial highlights

• FY 2026 operating revenue grew 10% year-on-year, led by biosimilars, excluding one-time generic lenalidomide impact; consolidated revenue for FY26 was Rs. 1,69,270 million, up from Rs. 1,52,617 million in FY25.

• Biosimilars revenue up 12% year-on-year; generics (ex-lenalidomide) up 13%; CRDMO up 2% year-on-year.

• EBITDA at INR 1,073 crore, margin 23%; adjusted EBITDA up 29% year-on-year.

• Reported net profit for FY 2026 before exceptionals at INR 436 crore; consolidated net profit for FY26 was Rs. 3,688 million, compared to Rs. 14,294 million in FY25.

• Earnings per share (consolidated, annualized) for FY26 was Rs. 2.82, down from Rs. 8.46 in FY25.

Outlook and guidance

• FY 2027 expected to benefit from recent product launches, with performance improving progressively, especially in the second half as new products scale.

• Biosimilars to drive continued growth and operating leverage; generics to focus on profitability as utilization improves.

• No major CapEx planned; focus on execution, consolidation, and sustainable margin improvement.

• Integration of BBL expected to deliver operational synergies, unified capital allocation, and value maximization.

• Board expects the corporate restructuring to simplify structure and enhance stakeholder value.